Global Microbubbles/Ultrasound Contrast Agents Market

Microbubbles/Ultrasound Contrast Agents Comprehensive Study by Type (Cardiovascular Diseases, Renal Diseases, Others), Application (Molecular Imaging, Gene Therapy, Drug Delivery, Stem Cells Delivery) Players and Region - Global Market Outlook to 2030

Microbubbles/Ultrasound Contrast Agents Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 25.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
the rise in the incidence of chronic diseases is expected to boost the growth of the microbubbles/ultrasound contrast agents market during the forecast period. Microbubbles are used for contrast ultrasound imaging as blood-pool agents in cardiology and radiology. Their promise as targeted agents for molecular imaging is now being recognized. Microbubbles can be functionalized with ligand molecules that bind to molecular markers of disease. Additionally, increasing need to monitor the status of the biomarker in vascular endothelium, visualizing tumor vasculature, imaging inflammation, and the increasing requirement for targeted therapies further drive the adoption of microbubbles/ultrasound contrast agents in molecular imaging.

The Global Microbubbles/Ultrasound Contrast Agents market presents a comprehensive analysis of the Microbubbles/Ultrasound Contrast Agents market by product type (Cardiovascular Diseases, Renal Diseases and Others), by end-user/application (Molecular Imaging, Gene Therapy, Drug Delivery and Stem Cells Delivery), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. The key Players profiled in the report are Lantheus Holdings (United States), Bracco (Italy), GE Healthcare (United States), Daiichi Sankyo (Japan), NanoPET Pharma (Germany), Bristol-Myers Squibb (United States), Bayer Healthcare Pharmaceuticals (Germany), Medrad Inc. (United States), Lantheus Medical (United States) and ACIST Medical Systems (United States). Additionally, other players that are part of this comprehensive study are AMAG Pharmaceuticals, Inc (United States), Canadian Imaging (United States) and NanoScan Imaging (United States).

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Key Companies ProfiledLantheus Holdings (United States), Bracco (Italy), GE Healthcare (United States), Daiichi Sankyo (Japan), NanoPET Pharma (Germany), Bristol-Myers Squibb (United States), Bayer Healthcare Pharmaceuticals (Germany), Medrad Inc. (United States), Lantheus Medical (United States) and ACIST Medical Systems (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Growth in Mortality Associated with a Heart Attack and Stroke and The Upsurge in Demand for Advanced Diagnostic Technologies

Market Growth Drivers:
The Rise in the Prevalence of Various Chronic Cardiovascular Diseases and High Adoption for Microbubbles in Echocardiography Imaging Procedures

Challenges:
Complexity Involved in Conducting Contrast-Enhanced Ultrasound (CEUS) Procedures

Restraints:
They Don’t Last for Long in Circulation

Opportunities:
Advancement in ultrasound technologies and Increase in Demand for Targeted Diagnostic Tools

Regional Breakdown and Segment Analysis
This section of our report presents a realistic picture of the Global Microbubbles/Ultrasound Contrast Agents industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in the geographical region of interest.

Microbubbles/Ultrasound Contrast Agents is market fragmented with several key players .
The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)

Report Objectives / Segmentation Covered

By Type
  • Cardiovascular Diseases
  • Renal Diseases
  • Others
By Application
  • Molecular Imaging
  • Gene Therapy
  • Drug Delivery
  • Stem Cells Delivery
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rise in the Prevalence of Various Chronic Cardiovascular Diseases
      • 3.2.2. High Adoption for Microbubbles in Echocardiography Imaging Procedures
    • 3.3. Market Challenges
      • 3.3.1. Complexity Involved in Conducting Contrast-Enhanced Ultrasound (CEUS) Procedures
    • 3.4. Market Trends
      • 3.4.1. Growth in Mortality Associated with a Heart Attack and Stroke
      • 3.4.2. The Upsurge in Demand for Advanced Diagnostic Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Microbubbles/Ultrasound Contrast Agents, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Microbubbles/Ultrasound Contrast Agents (Value)
      • 5.2.1. Global Microbubbles/Ultrasound Contrast Agents by: Type (Value)
        • 5.2.1.1. Cardiovascular Diseases
        • 5.2.1.2. Renal Diseases
        • 5.2.1.3. Others
      • 5.2.2. Global Microbubbles/Ultrasound Contrast Agents by: Application (Value)
        • 5.2.2.1. Molecular Imaging
        • 5.2.2.2. Gene Therapy
        • 5.2.2.3. Drug Delivery
        • 5.2.2.4. Stem Cells Delivery
      • 5.2.3. Global Microbubbles/Ultrasound Contrast Agents Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Microbubbles/Ultrasound Contrast Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Lantheus Holdings (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bracco (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Daiichi Sankyo (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NanoPET Pharma (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol-Myers Squibb (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer Healthcare Pharmaceuticals (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Medrad Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lantheus Medical (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ACIST Medical Systems (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Microbubbles/Ultrasound Contrast Agents Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Microbubbles/Ultrasound Contrast Agents (Value)
      • 7.2.1. Global Microbubbles/Ultrasound Contrast Agents by: Type (Value)
        • 7.2.1.1. Cardiovascular Diseases
        • 7.2.1.2. Renal Diseases
        • 7.2.1.3. Others
      • 7.2.2. Global Microbubbles/Ultrasound Contrast Agents by: Application (Value)
        • 7.2.2.1. Molecular Imaging
        • 7.2.2.2. Gene Therapy
        • 7.2.2.3. Drug Delivery
        • 7.2.2.4. Stem Cells Delivery
      • 7.2.3. Global Microbubbles/Ultrasound Contrast Agents Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Microbubbles/Ultrasound Contrast Agents: by Type(USD Million)
  • Table 2. Microbubbles/Ultrasound Contrast Agents Cardiovascular Diseases , by Region USD Million (2018-2023)
  • Table 3. Microbubbles/Ultrasound Contrast Agents Renal Diseases , by Region USD Million (2018-2023)
  • Table 4. Microbubbles/Ultrasound Contrast Agents Others , by Region USD Million (2018-2023)
  • Table 5. Microbubbles/Ultrasound Contrast Agents: by Application(USD Million)
  • Table 6. Microbubbles/Ultrasound Contrast Agents Molecular Imaging , by Region USD Million (2018-2023)
  • Table 7. Microbubbles/Ultrasound Contrast Agents Gene Therapy , by Region USD Million (2018-2023)
  • Table 8. Microbubbles/Ultrasound Contrast Agents Drug Delivery , by Region USD Million (2018-2023)
  • Table 9. Microbubbles/Ultrasound Contrast Agents Stem Cells Delivery , by Region USD Million (2018-2023)
  • Table 10. South America Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2018-2023)
  • Table 11. South America Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 12. South America Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 13. Brazil Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 14. Brazil Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 15. Argentina Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 16. Argentina Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 17. Rest of South America Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 18. Rest of South America Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 19. Asia Pacific Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2018-2023)
  • Table 20. Asia Pacific Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 21. Asia Pacific Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 22. China Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 23. China Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 24. Japan Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 25. Japan Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 26. India Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 27. India Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 28. South Korea Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 29. South Korea Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 30. Taiwan Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 31. Taiwan Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 32. Australia Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 33. Australia Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 36. Europe Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2018-2023)
  • Table 37. Europe Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 38. Europe Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 39. Germany Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 40. Germany Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 41. France Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 42. France Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 43. Italy Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 44. Italy Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 45. United Kingdom Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 46. United Kingdom Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 47. Netherlands Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 48. Netherlands Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 49. Rest of Europe Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 50. Rest of Europe Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 51. MEA Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2018-2023)
  • Table 52. MEA Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 53. MEA Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 54. Middle East Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 55. Middle East Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 56. Africa Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 57. Africa Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 58. North America Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2018-2023)
  • Table 59. North America Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 60. North America Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 61. United States Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 62. United States Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 63. Canada Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 64. Canada Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 65. Mexico Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2018-2023)
  • Table 66. Mexico Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2018-2023)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Microbubbles/Ultrasound Contrast Agents: by Type(USD Million)
  • Table 78. Microbubbles/Ultrasound Contrast Agents Cardiovascular Diseases , by Region USD Million (2025-2030)
  • Table 79. Microbubbles/Ultrasound Contrast Agents Renal Diseases , by Region USD Million (2025-2030)
  • Table 80. Microbubbles/Ultrasound Contrast Agents Others , by Region USD Million (2025-2030)
  • Table 81. Microbubbles/Ultrasound Contrast Agents: by Application(USD Million)
  • Table 82. Microbubbles/Ultrasound Contrast Agents Molecular Imaging , by Region USD Million (2025-2030)
  • Table 83. Microbubbles/Ultrasound Contrast Agents Gene Therapy , by Region USD Million (2025-2030)
  • Table 84. Microbubbles/Ultrasound Contrast Agents Drug Delivery , by Region USD Million (2025-2030)
  • Table 85. Microbubbles/Ultrasound Contrast Agents Stem Cells Delivery , by Region USD Million (2025-2030)
  • Table 86. South America Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2025-2030)
  • Table 87. South America Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 88. South America Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 89. Brazil Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 90. Brazil Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 91. Argentina Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 92. Argentina Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 93. Rest of South America Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 94. Rest of South America Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 95. Asia Pacific Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2025-2030)
  • Table 96. Asia Pacific Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 97. Asia Pacific Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 98. China Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 99. China Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 100. Japan Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 101. Japan Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 102. India Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 103. India Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 104. South Korea Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 105. South Korea Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 106. Taiwan Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 107. Taiwan Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 108. Australia Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 109. Australia Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 110. Rest of Asia-Pacific Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 111. Rest of Asia-Pacific Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 112. Europe Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2025-2030)
  • Table 113. Europe Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 114. Europe Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 115. Germany Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 116. Germany Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 117. France Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 118. France Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 119. Italy Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 120. Italy Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 121. United Kingdom Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 122. United Kingdom Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 123. Netherlands Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 124. Netherlands Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 125. Rest of Europe Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 126. Rest of Europe Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 127. MEA Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2025-2030)
  • Table 128. MEA Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 129. MEA Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 130. Middle East Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 131. Middle East Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 132. Africa Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 133. Africa Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 134. North America Microbubbles/Ultrasound Contrast Agents, by Country USD Million (2025-2030)
  • Table 135. North America Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 136. North America Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 137. United States Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 138. United States Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 139. Canada Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 140. Canada Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 141. Mexico Microbubbles/Ultrasound Contrast Agents, by Type USD Million (2025-2030)
  • Table 142. Mexico Microbubbles/Ultrasound Contrast Agents, by Application USD Million (2025-2030)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Microbubbles/Ultrasound Contrast Agents: by Type USD Million (2018-2023)
  • Figure 5. Global Microbubbles/Ultrasound Contrast Agents: by Application USD Million (2018-2023)
  • Figure 6. South America Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 7. Asia Pacific Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 8. Europe Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 9. MEA Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 10. North America Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 11. Global Microbubbles/Ultrasound Contrast Agents share by Players 2023 (%)
  • Figure 12. Global Microbubbles/Ultrasound Contrast Agents share by Players (Top 3) 2023(%)
  • Figure 13. Global Microbubbles/Ultrasound Contrast Agents share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Lantheus Holdings (United States) Revenue, Net Income and Gross profit
  • Figure 16. Lantheus Holdings (United States) Revenue: by Geography 2023
  • Figure 17. Bracco (Italy) Revenue, Net Income and Gross profit
  • Figure 18. Bracco (Italy) Revenue: by Geography 2023
  • Figure 19. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 20. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 21. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Daiichi Sankyo (Japan) Revenue: by Geography 2023
  • Figure 23. NanoPET Pharma (Germany) Revenue, Net Income and Gross profit
  • Figure 24. NanoPET Pharma (Germany) Revenue: by Geography 2023
  • Figure 25. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 27. Bayer Healthcare Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer Healthcare Pharmaceuticals (Germany) Revenue: by Geography 2023
  • Figure 29. Medrad Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Medrad Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Lantheus Medical (United States) Revenue, Net Income and Gross profit
  • Figure 32. Lantheus Medical (United States) Revenue: by Geography 2023
  • Figure 33. ACIST Medical Systems (United States) Revenue, Net Income and Gross profit
  • Figure 34. ACIST Medical Systems (United States) Revenue: by Geography 2023
  • Figure 35. Global Microbubbles/Ultrasound Contrast Agents: by Type USD Million (2025-2030)
  • Figure 36. Global Microbubbles/Ultrasound Contrast Agents: by Application USD Million (2025-2030)
  • Figure 37. South America Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 38. Asia Pacific Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 39. Europe Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 40. MEA Microbubbles/Ultrasound Contrast Agents Share (%), by Country
  • Figure 41. North America Microbubbles/Ultrasound Contrast Agents Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Lantheus Holdings (United States)
  • Bracco (Italy)
  • GE Healthcare (United States)
  • Daiichi Sankyo (Japan)
  • NanoPET Pharma (Germany)
  • Bristol-Myers Squibb (United States)
  • Bayer Healthcare Pharmaceuticals (Germany)
  • Medrad Inc. (United States)
  • Lantheus Medical (United States)
  • ACIST Medical Systems (United States)
Additional players considered in the study are as follows:
AMAG Pharmaceuticals, Inc (United States) , Canadian Imaging (United States) , NanoScan Imaging (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 233 Pages 69 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Microbubbles/Ultrasound Contrast Agents Market Quantitative research analysis
Global Microbubbles/Ultrasound Contrast Agents Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Microbubbles/Ultrasound Contrast Agents market is predicted to grow at a CAGR of 25.2% between 2023 - 2030.
Global Microbubbles/Ultrasound Contrast Agents market is restrained by They Don’t Last for Long in Circulation.
The Microbubbles/Ultrasound Contrast Agents market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.

Know More About Global Microbubbles/Ultrasound Contrast Agents Market Report?

Have a Query? Click Here

Other Related Reports

Hepatitis Test Solution Comprehensive Study by Disease Type (Hepatitis B, Hepatitis C, Others), Technology (ELISA, Rapid Diagnostics Test, PCR, INAAT, Others), End User (Hospitals & Diagnostics Labs,...
$ 3450
Behcets Disease Comprehensive Study by Application (Men, Women, Others), Affected body part (Mouth, Skin, Genitals, Eyes, Joints, Blood Vessels, Digestive System, Brain), Treatment (Corticosteroids ...
$ 3750
Montelukast Intermediate Comprehensive Study by Application (Asthma, Allergic rhinitis, Bronchospasm, Urticaria) Players and Region - Global Market Outlook to 2030
$ 3500
Oral Thrush Comprehensive Study by Type (Pseudomembranous, Erythematous, Hyperplastic, Others), Application (Hospitals, Clinics), Diagnosis Methods (Examination, Biopsy, Endoscopy, Others.), Treatmen...
$ 3450
Treatment for Communicable Diseases Comprehensive Study by Type (Therapeutics (Antibiotics, Antifungal, Antivirals, Antiparasitics, Others), Vaccines), Application (Hospital, Clinic, Other), Diseases...
$ 3750
Injectable Anti-Wrinkle Comprehensive Study by Type (Muscle Relaxants (Botox Injections, Others), Synthetic Wrinkle Fillers (Sculptra, Radiesse, Silicone), Autologous Wrinkle Fillers, Muscle Relaxant...
$ 3750